Transforming Diabetes care with a breakthrough cell therapy
Generating immuno-cloaked iPSC-Derived βeta Cells
Our team utilizes immuno-cloaked human induced pluripotent stem cells (iPSCs) as a platform to develop glucose responsive beta-islet cells, ready for transplantation. We have successfully developed a new, state-of-the-art method to generate beta cells from iPSCs that display glucose induced insulin responsiveness on par to native beta islets.
Insulin Independence
Post-transplantation, patients will no longer rely on daily insulin injections or constant glucose monitoring. This single, transformative therapy will restore the body’s natural ability to control blood sugar, replacing the burden of lifelong management with true physiological insulin production. This is the future we’re working to deliver: one where diabetes care moves from maintenance to liberation.